NCT03757650 is a Phase 4 clinical trial of Bismuth Subsalicylate in Helicobacter Pylori Infection, sponsored by Fatih Sultan Mehmet Training and Research Hospital.

Who is sponsoring NCT03757650?

NCT03757650 is sponsored by Fatih Sultan Mehmet Training and Research Hospital.

What drugs are being tested in NCT03757650?

Interventions in NCT03757650: Bismuth Subsalicylate.

What condition does NCT03757650 study?

NCT03757650 studies Helicobacter Pylori Infection, Obesity, Morbid.

Is NCT03757650 still recruiting?

NCT03757650 is currently completed. Last updated 23 March 2021.

Last reviewed 2021-03-23 · How we verify

NCT03757650

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

THE EFFECT OF HELICOBACTER PYLORI ERADICATION THERAPY TO GASTRIC WALL THICKNESS BEFORE THE LAPAROSCOPIC SLEEVE GASTRECTOMY

Completed Phase 4 Last updated 23 March 2021

What this trial tests

Phase 4 trial testing Bismuth Subsalicylate in Helicobacter Pylori Infection in 3 participants. Completed in 1 February 2021.

Timeline

1 October 2018

Primary endpoint
1 November 2020

1 February 2021

Quick facts

Lead sponsor	Fatih Sultan Mehmet Training and Research Hospital
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	prevention
Enrollment	3
Start date	1 October 2018
Primary completion	1 November 2020
Estimated completion	1 February 2021
Sites	1 location across Turkey (Türkiye)

Drugs / interventions tested

Bismuth Subsalicylate (bismuth subsalicylate) — full drug profile →

Conditions studied

Helicobacter Pylori Infection — all drugs for Helicobacter Pylori Infection →
Obesity, Morbid — all drugs for Obesity, Morbid →

Sponsor

Fatih Sultan Mehmet Training and Research Hospital

Who can join

Adults 18 to 70, any sex, with Helicobacter Pylori Infection or Obesity, Morbid. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Laparoscopic sleeve gastrectomy is one of the most popular bariatric surgery in the world. The most important complication about this surgery that the leakage from the stapler line because of the inconvenient stapler choice..The stapler colour has to be chosen to the gastric wall thickness. It is not known well that the effect of Helicobacter pylori to gastric wall thickness Nobody pay any attention about being Helicobacter pylori positive when they are choosing stapler colour during the Laparoscopic sleeve gastrectomy so that everybody use the same type of stapler in Helicobacter pylori positive and negative patients during the Laparoscopic sleeve gastrectomy .Because of this inconvenient staplers use in the Laparoscopic sleeve gastrectomy the risk of leakage would be increase. Purpose of this research is that what is the effect of Helicobacter pylori to the gastric wall thickness and if the patients who will undergo Laparoscopic sleeve gastrectomy take the Helicobacter pylori eradication therapy before the surgery will gastric wall thickness increase or decrease. .

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Bismuth Subsalicylate

Trials testing the same drug.

NCT03592082 — Use of Bismuth Subsalicylate in Clostridium Difficile Colitis · Phase 4 · withdrawn
NCT00002682 — Antibiotic Therapy and Antacids in Patients With Malt Lymphoma of the Stomach · Phase 2 · completed

Other recruiting trials for Helicobacter Pylori Infection

Currently open trials in the same condition.

NCT07285096 — P-CABs-based Bismuth Quadruple Therapy for Helicobacter Pylori Eradication · recruiting
NCT07358130 — Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy and Bismuth Quadruple Therapy · NA · recruiting
NCT07165444 — Potassium-Competitive Acid Blocker Versus Proton Pump Inhibitor as A Part of Bismuth Based Quadruple Therapy for Treatme · NA · recruiting
NCT06929962 — VA Dual Sequential Therapy · Phase 4 · recruiting
NCT06959368 — Vonoprazan Evaluation Compared to Standard Triple Therapy in Helicobacter Pylori eRadication · Phase 4 · recruiting

Other Fatih Sultan Mehmet Training and Research Hospital trials

Trials by the same sponsor.

NCT07589582 — Active Noise-Cancelling Headphones Reduce Operative Time and Improve Procedural Consistency in ACL Reconstruction l · NA · active not recruiting
NCT07523828 — Laryngeal Edema Assessment by Cuff Leak Test and Ultrasound in ICU Patients and Its Relationship With Weaning Success · not yet recruiting
NCT07487038 — The Efficacy and Safety of a Single-Dose Hyaluronic Acid Injection in the Treatment of Knee Osteoarthritis · not yet recruiting
NCT07485465 — Lymphoedema Diagnosis and Treatment · not yet recruiting
NCT07451925 — Prediction of Postoperative Pain Using Venous Cannulation Pain and Preoperative Anxiety Scores · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03757650 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fatih Sultan Mehmet Training and Research Hospital
Last refreshed: 23 March 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03757650.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing